EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

(1-((2S,3S,5R)-2-(Hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methyl (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylate

Pengzhen Zhu, Wai Kin Lam, Yuhan Xie, Paolo Coghi

Molbank · 2026-11-06 · 2026 (6) · M2255

DOI: 10.3390/m2255 ↗

At a glance

Journal article in Molbank, published online on 2026-11-06. Written by Pengzhen Zhu and 3 co-authors. 22 references. The full text is freely available (open access, CC BY 4.0). Funded by: Macau University of Science and Technology.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

A novel celastrol–AZT conjugate containing a 1,2,3-triazole linker was designed and synthesized through copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC). A C29 propargyl ester of celastrol was first prepared and subsequently coupled with AZT to afford the target. The structure of 3 was characterized by 1H and 13C NMR spectroscopy, HSQC, COSY, DEPT-90, DEPT-135, FTIR, UV–Vis spectroscopy, and high-resolution mass spectrometry. The spectroscopic data supported retention of the celastrol core and successful formation of the triazole-linked nucleoside conjugate. In silico physicochemical and ADMET analyses suggested that introduction of the AZT moiety altered the lipophilic and permeability profile of the parent scaffold. The resulting conjugate expands the chemical space of C29-modified celastrol derivatives and provides a structurally characterized hybrid scaffold for further biological and physicochemical investigation.

Funding

  • Macau University of Science and Technology

Cite

APA

Zhu, P., Lam, W. K., Xie, Y., & Coghi, P. (2026). (1-((2S,3S,5R)-2-(Hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methyl (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylate. Molbank, 2026(6), M2255. https://doi.org/10.3390/m2255

Vancouver

Zhu P, Lam WK, Xie Y, Coghi P. (1-((2S,3S,5R)-2-(Hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methyl (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylate. Molbank. 2026;2026(6):M2255. doi:10.3390/m2255

BibTeX
@article{Zhu2026,
  author = {Zhu, Pengzhen and Lam, Wai Kin and Xie, Yuhan and Coghi, Paolo},
  title = {(1-((2S,3S,5R)-2-(Hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methyl (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylate},
  journal = {Molbank},
  year = {2026},
  volume = {2026},
  number = {6},
  pages = {M2255},
  doi = {10.3390/m2255}
}
Start for free →